CN1769460A - Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug - Google Patents
Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug Download PDFInfo
- Publication number
- CN1769460A CN1769460A CN 200510042988 CN200510042988A CN1769460A CN 1769460 A CN1769460 A CN 1769460A CN 200510042988 CN200510042988 CN 200510042988 CN 200510042988 A CN200510042988 A CN 200510042988A CN 1769460 A CN1769460 A CN 1769460A
- Authority
- CN
- China
- Prior art keywords
- grb7
- ring
- bamh
- her2
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention discloses a structure method for the Cb1-Grb7 (SH2)-RING eukaryote expression carrier of the recomposed inserting Cb1 ligase, wherein the composed expression plasmid pcDNA3.1 (+)-Cb1-Grb7 (SH2)-RING can be used as the gene medicament of the anti-EGFR or anti-HER2 masculine tumour. It is proved by the experiment that after the Cb1-Grb7 (SH2)-RING catching with the HER2 masculine clung carcinomaan cell A549 or the HER2 masculine galactophore carcinomaan cell SK-BR-3, it restrains from the cell proliferation coming from excessive activating with the EGFR or the HER2 by accelerating them to move down, so it has the anti-EGFR or anti-HER2 masculine tumour use.
Description
Technical field
The invention belongs to field of tumor gene therapy, relate to reorganization chimeric Cbl ubiquitin ligase Cbl-Grb7 (SH2)-RING Construction of eukaryotic and be used for the purposes of the genomic medicine of the anti-EGFR positive or HER2 positive tumor.
Background technology
Cbl (Casitas B-lineage lymphoma) is the plasmosin that a class is evolved and upward guarded, extensively distribute, form by 906 amino acid, include a plurality of different structural domains, can mediate with different cells in the molecule combination, therefore in the cell activation process, can be used as linkers or support molecule and participate in signal transduction; The function that intramolecular RING structural domain of while is given the Cbl ubiquitin ligase promotes its bonded target molecule generation ubiquitinization, downward modulation, thereby participates in the negative regulation mechanism of intracellular signal transduction.Cbl sudden change or dysfunction can cause cell to take place to transform or immune dysfunction.
1.Cbl structure and function
(1) Cbl contains a plurality of protein-protein binding domainss and a RING structural domain
Cbl albumen begins to contain respectively Tyrosylprotein kinase binding domains (TKB), Linker, RING structural domain, proline rich district, C-terminal several tyrosine phosphorylations site and leucine zipper by N-terminal.Wherein the TKB structural domain is made of the SH2 of 4H, EF and variation, identification and in conjunction with activated protein Tyrosylprotein kinase PTK.The RING mediation combines with ubiquitin binding enzyme E2.Linker has vital role for the best spatial location that keeps forming between bonded substrate, RING and the E2 three on the Cbl molecule.The proline rich domain and the tyrosine site of C end mediate Cbl molecule and other protein binding that contains SH3 or contain SH2 respectively.
(2) Cbl promotes multiple protein Tyrosylprotein kinase ubiquitinization, downward modulation as ubiquitin ligase, participates in the negative regulation of intracellular signal transduction
The multivalence binding ability of Cbl molecule has determined it to participate in signal transduction pathway as a kind of multivalence linkers on the one hand.On the other hand, it is a kind of ubiquitin ligase in itself that RING has given Cbl albumen, TKB in the molecule and other structural domains can be discerned and in conjunction with target protein, RING is responsible for raising ubiquitin binding enzyme E2 and the ubiquitin that will be combined on the E2 is transferred on its bonded substrate molecule, thereby starts the ubiquitin degradation pathway.Cbl albumen promotes multiple receptor type protein tyrosine kinase (RTK) as EGFR, PDGFR α, β, CSF-1R, Met, Hck etc. part inductive ubiquitinization, degraded subsequently to take place by this way, participate in the negative regulation of intracellular signal transduction, this is significant for the homeostasis of keeping cell.And for many protein tyrosine kinases such as EGFR, Syk etc., Cbl N end truncate (comprising N-terminal to RING) is just be enough to impel substrate generation ubiquitinization.Can become cancer protein after the Cbl sudden change; Can escape after many carinogenicity RTK such as EGFRvV, CSF-1R, HER2 etc. the undergo mutation negative regulation effect of Cbl.These phenomenon promptings, the negative regulation effect of strengthening or rebuilding Cbl perhaps can suppress some tumor cell proliferation.
2. the recombinate application of chimeric ubiquitin ligase
Ubiquitin ligase E3 is responsible for specific recognition and bound substrates in the ubiquitin process.A plurality of in recent years study group use recombinant technology and make up the chimeric ubiquitin ligase of reorganization, are not some albumen of ubiquitin system natural substrate under the normal circumstances of successfully degrading.For example pass through to modify the chimeric F-box PROTEIN C FP of the substrate of ubiquitin ligase mixture Skpl-Cullin1-F-box (SCF), target degraded pRB and β-catenin in conjunction with the F-box of subunit formation.After recombinating from two RING of BRCA1 and BARD and proliferating cell nuclear antigen PCNA respectively, this recombinant molecule reduces the proteic level of p57 in the mode that proteasome relies on, and reduces its function.These studies show that the ubiquitin ligase that utilizes reorganization, target ground degraded some diseases associated molecule.But also do not use the relevant report that recombinant C bl ubiquitin ligase carries out gene therapy research at present.
Summary of the invention
In view of the proteic SH2 of Cbl be responsible for identification and in conjunction with multiple activatory protein tyrosine kinase, for target ground carcinogenic associated protein EGFR of degraded and HER2, the objective of the invention is to, structure can the carcinogenic associated protein EGFR of target degraded and the chimeric Cbl ubiquitin ligase of reorganization of HER2 and being cloned in the eukaryon expression plasmid, is used for the purposes of the genomic medicine of anti-EGFR and HER2 positive tumor.
The present invention with the SH2 of Cbl albumen n end part be replaced into can in conjunction with and the SH2 of the downstream signaling molecule Grb7 of mediation EGFR and HER2 activation signals, make up recombinant chimeric Cbl-Grb7 (SH2)-RING, wherein the SH2 structural domain after the displacement is responsible for EGFR and the combination of HER2 target, and RING is responsible for that the ubiquitin molecule is connected to substrate and to promote them ubiquitinization, degraded takes place.
To achieve these goals, the technical solution taked of the present invention is:
1) BamH I and EcoR v are introduced the two ends that Cbl N holds encoding gene SH2, make up pcDNA3.1 (+)-CblN (BamH I+EcoR V)
The present invention utilizes PCR and overlapping elongation technology, designs 3 pairs of primers respectively, carries out 3 and takes turns the PCR reaction, and the SH2N end of at first BamH I being introduced the CblN gene promptly obtains CblN (BamH I).With CblN (BamH I) is template, with method the SH2C end that EcoR V introduces the CblN gene is obtained CblN (BamH I+EcoR V).It is cloned into pGEM-T easy carrier checks order, utilizing the KpnI/XhoI enzyme to cut after order-checking is correct is inserted between the KpnI/XhoI restriction enzyme site of pcDNA3.1 (+) carrier for expression of eukaryon, promptly obtains pcDNA3.1 (+)-CblN (BamH I+EcoR V).
2) the SH2 gene fragment of amplification Grb7 and displacement are gone into pcDNA3.1 (+)-CblN (BamH I+EcoR are v) obtained eukaryon expression plasmid pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING of recombinant chimeric Cbl-Grb7 (SH2)-RING
CDNA with the SK-BR-3 cell is a template, the design primer amplification obtains the Grb7SH2 gene fragment and is cloned in the pGEM-T easy carrier, enzyme is cut and is identified and after order-checking confirms that sequence is correct, with BamH I and EcoR v double digestion the Grb7SH2 gene fragment is cut out, and pcDNA3.1 (+)-CblN that will cut through same enzyme (BamH I+EcoR v) carrier segment reclaims respectively, two fragments are carried out ligation through the T4 ligase enzyme, connect product transformed competence colibacillus cell DH5 α, picking mono-clonal overnight incubation, extract plasmid, after BamH I and the evaluation of EcoR v double digestion, to the segmental carrier of insertion that obtains the expection size confirmation of checking order again, called after pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING, this is the eukaryon expression plasmid of recombinant chimeric Cbl-Grb7 (SH2)-RING.
3) Cbl-Grb7 (SH2)-RING downward modulation EGFR or HER2 suppresses EGFR, HER2 male tumor cell proliferation
With plasmid pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING stable transfection EGFR male lung cancer cell line A549 and the HER2 male breast cancer cell line SK-BR-3 cell that successfully constructs, confirm that by immunoblotting, flow cytometer and cell experiment it by reducing the respective target molecular level, has effectively suppressed cell proliferation and the clonal expansion ability relevant with EGFR or HER2 overactivity.
Description of drawings
Fig. 1 is pcDNA3.1 (+) vector plasmid figure;
Fig. 2 cuts evaluation to the enzyme of pcDNA3.1 (+)-CblN (BamH I+EcoR V) carrier; Wherein:
1:pcDNA3.1 (+)-CblN (BamH I+EcoR V) is with Kpn I and Xho I double digestion;
2:pcDNA3.1 (+)-CblN is with Kpn I and Xho I double digestion;
3:pcDNA3.1 (+)-CblN (BamH I+EcoR V) is with BamH I and EcoR V double digestion;
4:pcDNA3.1 (+)-CblN is with BamH I and EcoR V double digestion;
M: known molecular amount standard substance.
Fig. 3 cuts evaluation to the enzyme of pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING carrier, wherein:
1:pcDNA3.1 (+)-CblN (BamH I+EcoR V) is with BamH I and EcoR V double digestion;
2:pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING is with BamH I and EcoR V double digestion;
M: known molecular amount standard substance.
Fig. 4 is the downward modulation effect of pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING recombinant plasmid to EGFR and HER2, wherein: a, stable transfection the A549 cell strain of pcDNA3.1 (+) empty plasmid (vector), pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING (being abbreviated as CblN/Grb7) give EGF and stimulate or do not stimulate, cell extract utilizes the antibody of anti-EGFR and ACTIN to carry out immunoblotting assay respectively.CblN/Grb7 can promote the EGFR downward modulation under the EGF stimulation.B, stable transfection the SK-BR-3 cell strain cell extract of pcDNA3.1 (+) empty plasmid (vector), pcDNA3.1 (+)-CblN (being abbreviated as CblN) and CblN/Grb7 utilize the antibody of anti-HER2 and ACTIN to carry out immunoblotting assay respectively.CblN/Grb7 can reduce HER2 albumen.
Fig. 5 is the inhibited proliferation of Cbl-Grb7 (SH2)-RING to EGFR male lung cancer cell line A549 and HER2 male breast cancer cell line SK-BR-3, wherein: a, stable transfection the A549 cell strain (writing a Chinese character in simplified form into a and a/g7 respectively) of pcDNA3.1 (+) empty plasmid and CblN/Grb7 give EGF and stimulated 3 days, utilize the proliferation activity of mtt assay comparative analysis cell before and after stimulating.CblN/Grb7 can suppress the cell proliferation under the EGF stimulation.B, stable transfection the SK-BR-3 cell strain of pcDNA3.1 (+) empty plasmid (control) and CblN/Grb7, be inoculated in the 60mm culture dish with 200 cell count and cultivated 14 days, calculate cloning efficiency.CblN/Grb7 can suppress the clonal expansion ability of SK-BR-3 cell.
The present invention is described in further detail with experiment below in conjunction with accompanying drawing.
Embodiment
Below be that (structure of pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING) and evaluation and this plasmid are to the restraining effect of EGFR and HER2 male growth of tumour cell for the chimeric Cbl ubiquitin ligase of reorganization Cbl-Grb7 (SH2)-RING eukaryon expression plasmid of providing of contriver.
1. the recombinate structure of chimeric Cbl ubiquitin ligase Cbl-Grb7 (SH2)-RING eukaryon expression plasmid
1.1 experiment material
Restriction enzyme, T4 ligase enzyme are all purchased the precious living biological company limited in Dalian, and recombinant mammalian expressing vector pcDNA3.1 (+) purchases the company in Invitrogen, and pcDNA3.1 (+) plasmid figure is referring to Fig. 1.Among the figure, P
CMV: the CMV promotor, the 232-819 bit base, T7:T7 promotor/primer sites, 863-882 bit base, polyclone restriction enzyme site: 895-1010 bit base, BGHpA: Trobest polyadenylation sequence, the 1028-1252 bit base, fl ori:fl initiation site, 1296-1726 bit base, SV40 ori:SV40 initiation site, the 1731-2074 bit base, Neomycin: neomycin resistance gene, 2136-2930 bit base, the SV40pA:SV40 polyadenylation signal, the 3104-3234 bit base, pUC ori:pUC initiation site, 3617-4287 bit base, Amipicilin: penbritin drug resistance gene, 4432-5428 bit base.
1.2 recombinant chimeric Cbl-Grb7 (the SH2)-RING eukaryon expression plasmid (building process of pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING)
At first utilize PCR and overlapping elongation technology, BamH I and EcoR v are introduced the two ends that Cbl N holds encoding gene SH2, it is cloned into pGEM-T easy carrier checks order, utilize the KpnI/XhoI enzyme to cut after order-checking is correct and be inserted between the KpnI/XhoI restriction enzyme site of pcDNA3.1 (+) carrier for expression of eukaryon, be i.e. pcDNA3.1 (+)-CblN (BamH I+EcoR V).Utilize PCR to obtain the Grb7SH2 gene fragment and be cloned in the pGEM-T easy carrier, enzyme is cut and is identified and after order-checking confirms that sequence is correct, with BamH I and EcoR v double digestion Grb7 SH2 gene fragment is cut out, and with pcDNA3.1 (+)-CblN that cuts through same enzyme (BamH I+EcoR carries out ligation after v) the carrier segment reclaims respectively, connect product transformed competence colibacillus cell DH5 α, picking mono-clonal overnight incubation, extract plasmid, after BamH I and the evaluation of EcoR v double digestion, to the segmental carrier of insertion that obtains the expection size confirmation of checking order again, called after pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING, this is the eukaryon expression plasmid of recombinant chimeric Cbl-Grb7 (SH2)-RING.
2. the influence of the on cell proliferation behind chimeric Cbl ubiquitin ligase Cbl-Grb7 (SH2)-RING eukaryon expression plasmid stable transfection EGFR or the HER2 male tumor cell line of recombinating
With the A549 cell of logarithmic phase or SK-BR-3 cell with every hole 2 * 10
5Cell inoculation is in 6 well culture plates, and nutrient solution is DMEM (GIBCO Co), and 10% calf serum (Hangzhou folium ilicis chinensis biological factory) is cultivated in CO2gas incubator (37 ℃).Next day is when growing to 90-95% when cell, according to Lipofectamine
TM2000 specification sheetss carry out liposome transfection.24h went down to posterity according to 1: 10 after transfection, and 48h begins to screen with the G418 of 400 μ g/mL, obtained the cell strain of stable transfection.Control cells is with same method transfection empty plasmid pcDNA3.1 (+) and screen stable cell line.The expression that detects Cbl-Grb7 (SH2)-RING by immunoblotting, flow cytometer and cell experiment is to the influence of EGFR or HER2 protein level, cell proliferation.
When applying to tumour patient, plan this plasmid with liposome after the injection of the local knurl body of row; Perhaps further Cbl-Grb7 (SH2)-RING is building up in the adenovirus carrier, behind acquisition Cbl-Grb7 (SH2)-RING recombinant adenovirus, utilizes the recombinant adenovirus of suitable titre to carry out local knurl body injection.
Technique effect of the present invention is:
1. made up eukaryon expression plasmid pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RING of recombinant chimeric Cbl-Grb7 (SH2)-RING, cut evaluation (Fig. 2,3) and determined dna sequence proves that sequence is entirely true through enzyme.
2. the influence of chimeric Cbl ubiquitin ligase Cbl-Grb7 (SH2)-RING of recombinating to the positive breast cancer cell SK-BR-3 of EGFR positive lung cancer cell A549 or HER2 cell proliferation
2.1 downward modulation EGFR and HER2 albumen
Immunoblotting assay shows, compares with the control cells strain of stable transfection pcDNA3.1 (+), and the downward modulation of ligand-dependent takes place EGFR in the A549 cell of stably express Cbl-Grb7 (SH2)-RING; HER2 downward modulation (Fig. 4) in the SK-BR-3 cell of stably express Cbl-Grb7 (SH2)-RING.Indirect IF staining and flow cytometry analysis cell surface HER2 expression prove that also latter HER2 positive rate is reduced to 41.2% (transfection the control cells strain of empty carrier be 89.6%).
2.2 suppress the growth of A549 stable transfected cells under EGF stimulates
The MTT experimental result shows, compares with the control cells strain of stable transfection pcDNA3.1 (+), and the A549 cell of stably express Cbl-Grb7 (SH2)-RING is suppressed to the stimulating growth effect of EGF that (Fig. 5 a).
2.3 suppress SK-BR-3 stable transfected cells strain propagation
The clone forms experiment and shows, compares with the control cells strain of stable transfection pcDNA3.1 (+), and the SK-BR-3 cloning efficiency of stably express Cbl-Grb7 (SH2)-RING reduces by 42% (Fig. 5 b).
Experimental results show that through above-mentioned, the chimeric Cbl ubiquitin ligase of reorganization Cbl-Grb7 (SH2)-RING eukaryon expression plasmid pcDNA3.1 (+)-Cbl-Grb7 (SH2)-RIHG that the present invention makes up, behind the positive breast cancer cell line SK-BR-3 of transfection EGFR positive lung cancer clone A549 or HER2, by promoting EGFR or HER2 downward modulation, suppressed effectively and EGFR or the relevant cell proliferation of HER2 overactivity, thereby had the purposes of anti-EGFR or HER2 positive tumor.
Claims (3)
1. the construction process of recombinant chimeric Cb1-Grb7 (SH2)-RING eukaryon expression plasmid is characterized in that:
At first BamH I and EcoRv are introduced the two ends that Cb1N holds encoding gene SH2, make up pcDNA3.1 (+)-Cb1N (BamH I+EcoR V); It is cloned into pGEM-T easy carrier checks order, utilize the KpnI/XhoI enzyme to cut after order-checking is correct and be inserted between the KpnI/XhoI restriction enzyme site of pcDNA3.1 (+) carrier for expression of eukaryon, promptly obtain pcDNA3.1 (+)-Cb1N (BamH I+EcoRV);
CDNA with the SK-BR-3 cell is a template again, the design primer amplification obtains Grb7 SH2 gene fragment, be cloned in the pGEM-T easy carrier, enzyme is cut and is identified and after order-checking confirms that sequence is correct, with BamH I and EcoR v double digestion Grb7 SH2 gene fragment is cut out, be inserted between the BamH I/EcoR V restriction enzyme site of pcDNA3.1 (+)-Cb1N (BamH I+EcoR V) carrier;
After BamH I and the evaluation of EcoRv double digestion, to the segmental carrier of insertion that obtains the expection size confirmation of checking order again, called after pcDNA3.1 (+)-Cb1-Grb7 (SH2)-RING is reorganization chimeric Cb1 ubiquitin ligase Cb1-Grb7 (SH2)-RING eukaryon expression plasmid.
2. recombinant chimeric Cb1-Grb7 (SH2)-RING eukaryon expression plasmid pcDNA3.1 (+)-Cb1-Grb7 (SH2)-RING is used to prepare the purposes of the genomic medicine of anti-EGFR or HER2 positive tumor.
3. purposes as claimed in claim 2, it is characterized in that, behind the positive breast cancer cell SK-BR-3 of recombinant chimeric Cb1-Grb7 (SH2)-RING eukaryon expression plasmid pcDNA3.1 (+)-Cb1-Grb7 (SH2)-RING transfection EGFR positive lung cancer cell A549 or HER2, by promoting EGFR or HER2 downward modulation, inhibition and EGFR or the relevant cell proliferation of HER2 overactivity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100429889A CN1314811C (en) | 2005-07-25 | 2005-07-25 | Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100429889A CN1314811C (en) | 2005-07-25 | 2005-07-25 | Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1769460A true CN1769460A (en) | 2006-05-10 |
| CN1314811C CN1314811C (en) | 2007-05-09 |
Family
ID=36751004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100429889A Expired - Fee Related CN1314811C (en) | 2005-07-25 | 2005-07-25 | Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314811C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012566A (en) * | 2011-09-26 | 2013-04-03 | 中国医学科学院基础医学研究所 | Non-phosphorylation ligand combined with Grb7 protein SH2 structural domain and pharmaceutical application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102174550B (en) * | 2011-01-28 | 2013-06-05 | 中国人民解放军第四军医大学 | Recombinant ubiquitin ligase PTB-U-box fusion gene and expression vector and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US5726020A (en) * | 1996-06-11 | 1998-03-10 | University Of Massachusetts | Inhibition of II synthesis |
-
2005
- 2005-07-25 CN CNB2005100429889A patent/CN1314811C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103012566A (en) * | 2011-09-26 | 2013-04-03 | 中国医学科学院基础医学研究所 | Non-phosphorylation ligand combined with Grb7 protein SH2 structural domain and pharmaceutical application thereof |
| CN103012566B (en) * | 2011-09-26 | 2015-04-08 | 中国医学科学院基础医学研究所 | Non-phosphorylation ligand combined with Grb7 protein SH2 structural domain and pharmaceutical application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1314811C (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100424096C (en) | Survivin mutant containing HIV transduction structural area and its preparation method and uses | |
| WO2019129174A1 (en) | Car-t cell targeting cd19 and expressing cd40 antibody at high level of stability, and use thereof | |
| CN102199218A (en) | Fusion protein of Her2 antibody and interleukin 2 and application thereof | |
| CN108753774A (en) | Interfere CD19-CAR-T cells and its application of IL-6 expression | |
| CN111205361B (en) | Interleukin 21 protein (IL21) mutant and application thereof | |
| CN1314811C (en) | Recombinant chimeric eucaryotic expression vector Cb1-Grb7(SH2)-RING and use of anti-tumour gene drug | |
| CN109666074A (en) | A kind of purposes of chemokine receptors CXCR5 | |
| CN100347307C (en) | Recombination chimeric molecule Cb1-Grb2(SH2)-RING eukaryotic expression plasmid and antitumor genetic medicine use | |
| CN108395480A (en) | Chimeric antigen receptor and its gene and recombinant expression carrier, CARHER2-NKT cells and its preparation method and application | |
| CN113583095B (en) | Antitumor polypeptide and application thereof | |
| CN102875684A (en) | FGFR single-stranded antibody fusion protein and application thereof in preparing targeting tumor cells medicines | |
| CN111410693B (en) | CDK5 resistant nano antibody and application thereof | |
| CN107502596A (en) | Express T cell and its application of the specificity TCRs of NY ESO 1 | |
| CN102586323B (en) | Method for constructing, expressing and purifying targeted immune fusion protein | |
| CN103232543A (en) | Recombinant protein Tumstatin-CD137L4 with Tumstatin activities as well as preparation method and application thereof | |
| CN102321178B (en) | Novel gonadotropin releasing hormone oriented fusion protein mutant | |
| WO2023070527A1 (en) | Condition-controlled spliceable chimeric antigen receptor molecule and application thereof | |
| CN114957441B (en) | Transgenic NK cells and application thereof in antitumor drugs | |
| CN102309755A (en) | Design scheme for compound type dual duplex locating type intracellular vaccine | |
| CN107557338A (en) | Specific recognition NY ESO 1 T cell and its united application with cell factor | |
| CN107737123B (en) | Cancer treatment medicine capable of killing tumor stem cells and application thereof | |
| CN102517312A (en) | Recombination ubiquitin ligase SH2-U-box fusion gene as well as expression vectors and applications thereof | |
| CN105985444A (en) | Chimeric antigen receptor, method for rapidly constructing chimeric antigen receptor, and application of chimeric antigen receptor | |
| CN103214580B (en) | Anti Her2 immune cytokine and application thereof | |
| ES2946554A1 (en) | PEPTIDES AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS (Machine-translation by Google Translate, not legally binding) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070509 Termination date: 20130725 |